Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.

Published

Journal Article

OBJECTIVE: To compare alternative class-sparing antiretroviral regimens in treatment-naive subjects. DESIGN: Open-label, multicenter, randomized trial of up to 3 consecutive treatment regimens over 96 weeks. METHODS: Two hundred ninety-one subjects received abacavir (ABC) and lamivudine and efavirenz (nonnucleoside reverse transcriptase inhibitors [NNRTIs]), ritonavir-boosted amprenavir (protease inhibitor [PI]), or stavudine (nucleoside reverse transcriptase inhibitor [NRTI]) by random assignment. The primary end points were the percentages of subjects with plasma HIV-1 RNA levels <400 copies/mL and time to treatment failure over 96 weeks. RESULTS: Ninety percent of subjects completed 96 weeks of follow-up, and 79% remained on study treatment. At week 96, there were no differences between arms in the percentages of subjects with plasma HIV-1 RNA levels <400 and <50 copies/mL, mean changes in plasma HIV-1 RNA levels, time to treatment failure, time to first or second virologic failure, or CD4 cell counts. The NNRTI arm had a greater percentages of subjects with RNA levels

Full Text

Duke Authors

Cited Authors

  • Bartlett, JA; Johnson, J; Herrera, G; Sosa, N; Rodriguez, A; Liao, Q; Griffith, S; Irlbeck, D; Shaefer, MS; Clinically Significant Long-Term Antiretroviral Sequential Sequencing Study (CLASS) Team,

Published Date

  • November 1, 2006

Published In

Volume / Issue

  • 43 / 3

Start / End Page

  • 284 - 292

PubMed ID

  • 16967040

Pubmed Central ID

  • 16967040

International Standard Serial Number (ISSN)

  • 1525-4135

Digital Object Identifier (DOI)

  • 10.1097/01.qai.0000243092.40490.26

Language

  • eng

Conference Location

  • United States